used Simoa assay to measure plasma proteins in cognitively unimpaired older adults (CU) and found that GFAP and p-tau181 were upregulated in the CU group with cerebral amyloidosis, which indicated the clinical potential of GFAP and p-tau for the diagnosis and longitudinal monitoring of preclinical AD. The gene discussed is MAPT; the disease is Alzheimer disease.